Ass. Prof. Josefsson (SE) talks about the randomized clinical trial which showed that adding docetaxel to bicalutamidein has a significant impact on prostate cancer progression in M0 patients with PSA relapse after curative treatment.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.I agreeRead More
